Interleukin-8 is not a predictive biomarker for the development of the acute promyelocytic leukemia differentiation syndrome.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read Online Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: BioMed Central Country of Publication: England NLM ID: 100967800 Publication Model: Electronic Cited Medium: Internet ISSN: 1471-2407 (Electronic) Linking ISSN: 14712407 NLM ISO Abbreviation: BMC Cancer Subsets: MEDLINE
    • Publication Information:
      Original Publication: London : BioMed Central, [2001-
    • Subject Terms:
      Antineoplastic Agents/*adverse effects ; Cell Differentiation/*drug effects ; Interleukin-8/*blood ; Leukemia, Promyelocytic, Acute/*blood ; Leukemia, Promyelocytic, Acute/*drug therapy ; Tretinoin/*adverse effects; Adult ; Aged ; Antineoplastic Agents/administration & dosage ; Biomarkers, Tumor/blood ; Female ; Humans ; Interleukin-6/blood ; Leukemia, Promyelocytic, Acute/complications ; Leukemia, Promyelocytic, Acute/pathology ; Male ; Middle Aged ; Retrospective Studies ; Syndrome ; Treatment Outcome ; Tretinoin/administration & dosage ; Young Adult
    • Abstract:
      Background: Differentiation syndrome (DS) is the main life-threatening adverse event that occurs in acute promyelocytic leukemia (APL) patients treated with all-trans retinoic acid (ATRA). Cytokine imbalances have been reported to play role during the developing of acute promyelocytic leukemia differentiation syndrome (APL-DS). However, the relationship between the plasma cytokine levels and their prognostic value for the prediction of DS developing in patients with APL during the treatment with ATRA and anthracyclines has not been previously reported.
      Methods: In this study, we followed an APL cohort (n = 17) over 7 days of ATRA therapy in DS (n = 6) and non-DS groups (n = 11). Interleukin (IL)-1β, IL-6, IL-8, IL-10, IL-12p70 and TNF-α were measured in the peripheral blood plasma from 17 patients with APL and 11 healthy adult controls by using the cytometric bead array method.
      Results: In non-DS patients, IL-8 plasma levels were significantly reduced in the seventh day of ATRA treatment (34.16; 6.99 to 147.11 pg mL - 1 in D0 vs. 10.9; 0 to 26.81 pg mL - 1 in D7; p = 0.02) whereas their levels did not discriminate between DS and non-DS development during the entire induction period (all p > 0.05 in D0, D3, and D7). No significant differences were found in IL-6 levels between groups (p > 0.05 in D0-D7). Other cytokines tested were all undetectable in patients with APL or healthy controls.
      Conclusions: We demonstrated that the modulation of IL-8 following ATRA treatment may occur regardless of the development of DS and, therefore, does not appear to be a predictive biomarker to monitor the APL-DS.
    • References:
      Leukemia. 2004 Mar;18(3):442-8. (PMID: 14749706)
      Blood. 2013 Mar 14;121(11):1935-43. (PMID: 23319575)
      Cytokine. 2013 Mar;61(3):885-91. (PMID: 23357299)
      Blood. 2010 Nov 18;116(20):4251-61. (PMID: 20679526)
      Crit Care Med. 2007 Mar;35(3):879-85. (PMID: 17235257)
      Leukemia. 1994 Oct;8(10):1750-7. (PMID: 7523800)
      Leukemia. 1996 Jan;10(1):95-101. (PMID: 8558945)
      Blood. 2015 May 14;125(20):3144-52. (PMID: 25810490)
      Br J Haematol. 2019 Oct;187(2):157-162. (PMID: 31410848)
      Leukemia. 2004 Oct;18(10):1662-70. (PMID: 15306822)
      Blood. 1997 Oct 1;90(7):2747-56. (PMID: 9326242)
      Oncotarget. 2017 Apr 18;8(16):27314-27327. (PMID: 28404891)
      Mediterr J Hematol Infect Dis. 2011;3(1):e2011048. (PMID: 22110898)
      Br J Haematol. 1999 Oct;107(1):86-98. (PMID: 10520028)
      Br J Haematol. 1996 May;93(2):360-6. (PMID: 8639429)
      J Leukoc Biol. 1994 Nov;56(5):559-64. (PMID: 7964163)
      Leuk Res. 2005 Jul;29(7):755-9. (PMID: 15927671)
      Blood. 2009 Jan 22;113(4):775-83. (PMID: 18945964)
      Blood. 2009 Feb 26;113(9):1875-91. (PMID: 18812465)
      Br J Haematol. 2010 Nov;151(3):209-20. (PMID: 20735400)
    • Grant Information:
      2013/08135-2 Fundação de Amparo à Pesquisa do Estado de São Paulo; 2016/02713-2 Fundação de Amparo à Pesquisa do Estado de São Paulo; 2017/23117-1 Fundação de Amparo à Pesquisa do Estado de São Paulo
    • Contributed Indexing:
      Keywords: Acute promyelocytic leukemia; Differentiation syndrome; Interleukin-6 (IL-6); Interleukin-8 (IL-8)
    • Accession Number:
      0 (Antineoplastic Agents)
      0 (Biomarkers, Tumor)
      0 (CXCL8 protein, human)
      0 (IL6 protein, human)
      0 (Interleukin-6)
      0 (Interleukin-8)
      5688UTC01R (Tretinoin)
    • Publication Date:
      Date Created: 20200830 Date Completed: 20210416 Latest Revision: 20210416
    • Publication Date:
      20231215
    • Accession Number:
      PMC7456372
    • Accession Number:
      10.1186/s12885-020-07330-1
    • Accession Number:
      32859169